Who can participate
- Children and adolescents with bone tumors who did not respond to treatment or for whom no treatment is available
- Age: 6 months to 18 years
Goal
In this study, zilovertamab vedotin is being used. Zilovertamab vedotin is still under investigation, and cannot be prescribed by doctors (outside of studies). It is therefore called an investigational drug. Zilovertamab vedotin is also called MK2140.
This is the first study to test zilovertamab vedotin in children. The goals of this study are:
- To see how safe the investigational drug is
- To see how well the investigational drug works and how long it works
- To test the investigational drug in different doses in patients with blood cancers and solid tumors
- To explore what zilovertamab vedotin does in the body
Background
There is still a need for more research into the treatment of bone cancer in children and adolescents. The investigational drug zilovertamab vedotin can find certain proteins that are present on cancer cells. This allows the investigational drug to attach to these cells and kill them. The investigational drug is being investigated by the sponsor for different types of tumors.